Thursday, 18 April 2024

Australia's most trusted
source of pharma news

Thursday, 18 April 2024
Listen to this story 

New pharma takes spending lead

Posted 2 April 2024 AM

An immense spend by a rival has seen Roche lose its crown as the pharma spending the most on research and development, after nearly a decade at the top.

Last year MSD spent US$30.53 billion on research, more than half of its total revenue for the year. The sky-high sum is largely a result of previous deals, including its purchases of Prometheus and Imago for a combined US$11.4 billion. The pharma also spent US$5.5 billion on a collaboration with Daiichi Sankyo on three antibody-drug conjugates, which could get up to US$22 billion if all future sales milestones are met.

To see the whole article, please login

Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (4)

Sales & Customer Relations (20)

Clinical & Medical, R&D (15)

Regulatory, Pharmacovigilance & QA (7)

Devices (1)

Other (32)

Email this article to a friend

Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.


Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.


Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).


You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.


You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.